Fig 1.
Distribution of cohort patients between impaired fasting glucose/diabetes and overweight/obesity analyses.
ART: antiretroviral therapy; BMI: body mass index; FPG: fasting plasma glucose; LFTU: lost to follow up. *Baseline for DM analysis defined as ≤180 days prior to ART start date. **Baseline for obesity analysis defined as BMI measured ≤180 days prior to ART start date or up to 30 days after ART start. †Post ART FPG measured ≥2 weeks after ART initiation. ‡Post ART BMI measured ≥180 days after ART initiation.
Table 1.
Baseline characteristics of participants.
Fig 2.
Kaplan-Meier curves representing risk of developing impaired fasting glucose /diabetes.
Pink line represents the risk of developing diabetes (DM) and blue line represents risk of the combined endpoint of impaired fasting glucose (IFG)/DM, from normoglycemic baseline as a function of the number of months of ART. DM defined as ≥1 fasting plasma glucose (FPG) ≥126, documented use of hypoglycemic medication, or DM diagnosis per the medical record. IFG defined as ≥1 FPG ≥ 100 mg/dl and no FPG ≥126 mg/dl. Vertical tick-marks indicate patients whose survival times have been right-censored. Dashed lines represent 95% confidence intervals.
Fig 3.
Kaplan-Meier curves representing risk of developing overweight/obese BMI.
Blue line represents risk of developing obesity and orange line represents risk of the combined endpoint of overweight/obese BMI from normal BMI at baseline as a function of the number of months of ART. Obesity was defined as BMI ≥30 kg/m2 and overweight as BMI ≥25 kg/m2. Vertical tick-marks indicate patients whose survival times have been right-censored. Dashed lines represent 95% confidence intervals.
Fig 4.
Burden of cardiometabolic comorbidities.
Venn diagram representing the burden of overlapping cardiometabolic morbidity within the cohort of patients initiating antiretroviral therapy, depicting the combined endpoints of impaired fasting glucose/diabetes mellitus (pink), overweight/obesity (yellow), and dyslipidemia (blue), and the percentage of overlapping prevalence of these disorders. Definitions of these outcomes can be found in methods section.